
- /
- Supported exchanges
- / TO
- / HBP.TO
Helix BioPharma Corp. (HBP TO) stock market data APIs
Helix BioPharma Corp. Financial Data Overview
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Helix BioPharma Corp. data using free add-ons & libraries
Get Helix BioPharma Corp. Fundamental Data
Helix BioPharma Corp. Fundamental data includes:
- Net Revenue:
- EBITDA: -9 567 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Helix BioPharma Corp. News

Helix Biopharma Corp. Announces Closure of Early Warrant Exercise Incentive Program | Raises Aggregate $3.21 Million
Toronto, Ontario --News Direct-- Helix BioPharma Corp. Helix BioPharma Corp. (Richmond Hill, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinica...


Helix Biopharma Corp. Announces Fiscal Third Quarter 2020 Results
RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, ...

Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results
RICHMOND HILL, Ontario, July 13, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for th...

Helix BioPharma Corp. to divest remaining ownership of Polish subsidiary
RICHMOND HILL, Ontario, June 26, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.